ARMR Sciences develops next-generation biodefense countermeasures using iMMUNOGEN technology to provide preventive protection against chemical and biological threats. The company focuses on creating organic molecule-based treatments designed for long-term, prophylactic use, starting with a fentanyl countermeasure. Their platform approach aims to deliver enduring protection for military and first responder applications, with potential expansion into broader patient populations.
Funding
Funding not disclosed
Founders
Product
Problem
Fentanyl overdoses are a leading cause of death in the United States, often occurring rapidly due to the drug's disruption of vital lung functions. Current interventions primarily address overdoses after they occur, rather than preventing them.
Solution
ARMR Sciences is developing a vaccine technology designed to provide immunity against fentanyl overdose and addiction. The vaccine works by stimulating the body's immune system to produce antibodies that neutralize fentanyl, preventing it from crossing the blood-brain barrier and blocking its euphoric effects. This proactive approach aims to save lives by preventing overdoses before they happen, offering a potential solution to the opioid crisis. The technology is currently undergoing clinical trials to establish its safety and efficacy.
Target Audience
The primary target audience includes individuals at high risk of fentanyl exposure and overdose, as well as public health organizations and government agencies seeking proactive solutions to combat the opioid crisis.
Features
- Vaccine technology designed to neutralize fentanyl upon exposure
- Stimulates the body's immune system to produce anti-fentanyl antibodies
- Prevents fentanyl from reaching the brain, blocking its euphoric effects
- Aims to prevent overdoses and deaths related to fentanyl addiction
- Currently undergoing clinical trials